--- title: "China NT Pharma Says Director’s Judicial Records Tied to Settled Subsidiary Loan, No Material Impact Seen" type: "News" locale: "en" url: "https://longbridge.com/en/news/286577625.md" description: "China NT Pharma Group announced that judicial records involving director Ng Tit are related to a settled loan dispute from a former subsidiary, Jiangsu Tailing Investment. The RMB119 million loan issue, linked to real estate, has been resolved without material impact on the company's operations or Ng's directorship. The company clarified that the records pertain to corporate guarantees, not personal misconduct." datetime: "2026-05-15T13:44:39.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286577625.md) - [en](https://longbridge.com/en/news/286577625.md) - [zh-HK](https://longbridge.com/zh-HK/news/286577625.md) --- # China NT Pharma Says Director’s Judicial Records Tied to Settled Subsidiary Loan, No Material Impact Seen ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks The latest announcement is out from China NT Pharma Group Co., Ltd. ( (HK:1011) ). China NT Pharma Group has issued a supplemental announcement detailing judicial procedure records involving director and chairman Ng Tit, arising from his role as legal representative of former subsidiary Jiangsu Tailing Investment. The matter stems from a RMB119 million loan dispute secured by real estate owned by Suzhou First Pharmaceutical, which led to a consumption restriction order against Jiangsu Tailing and corresponding restrictions on Mr. Ng under PRC law. Following the commencement of bankruptcy reorganization proceedings for Suzhou First Pharmaceutical, the secured creditor China Merchants Bank’s Suzhou branch was repaid in full from the collateral, and the relevant enforcement case has been folded into the reorganization and fully settled. The company emphasized that these records are linked to corporate guarantees rather than any personal misconduct by Mr. Ng and stated that the issues are not expected to materially affect the Group’s daily operations, financial position, or Mr. Ng’s ability to serve as a director. **More about China NT Pharma Group Co., Ltd.** China NT Pharma Group Co., Ltd. is a pharmaceutical company listed in Hong Kong that operates through various subsidiaries in mainland China. The Group’s activities include drug-related operations and investments, with entities such as Suzhou First Pharmaceutical Co., Ltd. and formerly Jiangsu Tailing Investment Co., Ltd. forming part of its corporate structure. **Average Trading Volume:** 317,450 **Technical Sentiment Signal:** Sell **Current Market Cap:** HK$597.9M For an in-depth examination of 1011 stock, go to TipRanks’ Overview page. ### Related Stocks - [01011.HK](https://longbridge.com/en/quote/01011.HK.md) - [03968.HK](https://longbridge.com/en/quote/03968.HK.md) - [600036.CN](https://longbridge.com/en/quote/600036.CN.md) ## Related News & Research - [China NT Pharma Calls 2026 AGM, Seeks Renewal of Share Issuance Mandate](https://longbridge.com/en/news/284750140.md) - [Should You Be Adding Daewoong Pharmaceutical (KRX:069620) To Your Watchlist Today?](https://longbridge.com/en/news/286824214.md) - [Investor interest in global proptech solutions surged last year. Here are three emerging opportunities to watch in 2026](https://longbridge.com/en/news/286681577.md) - [](https://longbridge.com/en/news/286948461.md) - [TwentyTwo Real Estate to Acquire Terhills Resort in Belgium from LRM](https://longbridge.com/en/news/286777893.md)